These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 23063726)
1. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Salem K; Brown CO; Schibler J; Goel A Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726 [TBL] [Abstract][Full Text] [Related]
2. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma. Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656 [TBL] [Abstract][Full Text] [Related]
5. NF-kappa B as a therapeutic target in multiple myeloma. Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748 [TBL] [Abstract][Full Text] [Related]
6. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts. Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Markovina S; Callander NS; O'Connor SL; Kim J; Werndli JE; Raschko M; Leith CP; Kahl BS; Kim K; Miyamoto S Mol Cancer Res; 2008 Aug; 6(8):1356-64. PubMed ID: 18708367 [TBL] [Abstract][Full Text] [Related]
8. Current status of bortezomib in the treatment of multiple myeloma. Cavo M Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361 [TBL] [Abstract][Full Text] [Related]
9. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
10. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312 [TBL] [Abstract][Full Text] [Related]
11. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Berenson JR; Ma HM; Vescio R Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821 [TBL] [Abstract][Full Text] [Related]
13. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786 [TBL] [Abstract][Full Text] [Related]
14. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Sung B; Kunnumakkara AB; Sethi G; Anand P; Guha S; Aggarwal BB Mol Cancer Ther; 2009 Apr; 8(4):959-70. PubMed ID: 19372569 [TBL] [Abstract][Full Text] [Related]
15. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Siveen KS; Mustafa N; Li F; Kannaiyan R; Ahn KS; Kumar AP; Chng WJ; Sethi G Oncotarget; 2014 Feb; 5(3):634-48. PubMed ID: 24504138 [TBL] [Abstract][Full Text] [Related]
16. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism]. Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142 [TBL] [Abstract][Full Text] [Related]
17. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Markovina S; Callander NS; O'Connor SL; Xu G; Shi Y; Leith CP; Kim K; Trivedi P; Kim J; Hematti P; Miyamoto S Mol Cancer; 2010 Jul; 9():176. PubMed ID: 20604947 [TBL] [Abstract][Full Text] [Related]
18. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Wang X; Li C; Ju S; Wang Y; Wang H; Zhong R Leuk Lymphoma; 2011 Oct; 52(10):1991-8. PubMed ID: 21718132 [TBL] [Abstract][Full Text] [Related]
19. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350 [TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]